Cargando…
A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya
OBJECTIVE: The objective was to measure the efficacy of the vaccination regimen FFM ME-TRAP in preventing episodes of clinical malaria among children in a malaria endemic area. FFM ME-TRAP is sequential immunisation with two attenuated poxvirus vectors (FP9 and modified vaccinia virus Ankara), which...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1617125/ https://www.ncbi.nlm.nih.gov/pubmed/17053830 http://dx.doi.org/10.1371/journal.pctr.0010029 |
_version_ | 1782130509983252480 |
---|---|
author | Bejon, Philip Mwacharo, Jedidah Kai, Oscar Mwangi, Tabitha Milligan, Paul Todryk, Stephen Keating, Sheila Lang, Trudie Lowe, Brett Gikonyo, Caroline Molyneux, Catherine Fegan, Greg Gilbert, Sarah C Peshu, Norbert Marsh, Kevin Hill, Adrian V. S |
author_facet | Bejon, Philip Mwacharo, Jedidah Kai, Oscar Mwangi, Tabitha Milligan, Paul Todryk, Stephen Keating, Sheila Lang, Trudie Lowe, Brett Gikonyo, Caroline Molyneux, Catherine Fegan, Greg Gilbert, Sarah C Peshu, Norbert Marsh, Kevin Hill, Adrian V. S |
author_sort | Bejon, Philip |
collection | PubMed |
description | OBJECTIVE: The objective was to measure the efficacy of the vaccination regimen FFM ME-TRAP in preventing episodes of clinical malaria among children in a malaria endemic area. FFM ME-TRAP is sequential immunisation with two attenuated poxvirus vectors (FP9 and modified vaccinia virus Ankara), which both deliver the pre-erythrocytic malaria antigen construct multiple epitope–thrombospondin-related adhesion protein (ME-TRAP). DESIGN: The trial was randomised and double-blinded. SETTING: The setting was a rural, malaria-endemic area of coastal Kenya. PARTICIPANTS: We vaccinated 405 healthy 1- to 6-year-old children. INTERVENTIONS: Participants were randomised to vaccination with either FFM ME-TRAP or control (rabies vaccine). OUTCOME MEASURES: Following antimalarial drug treatment children were seen weekly and whenever they were unwell during nine months of monitoring. The axillary temperature was measured, and blood films taken when febrile. The primary analysis was time to a parasitaemia of over 2,500 parasites/μl. RESULTS: The regime was moderately immunogenic, but the magnitude of T cell responses was lower than in previous studies. In intention to treat (ITT) analysis, time to first episode was shorter in the FFM ME-TRAP group. The cumulative incidence of febrile malaria was 52/190 (27%) for FFM ME-TRAP and 40/197 (20%) among controls (hazard ratio = 1.52). This was not statistically significant (95% confidence interval [CI] 1.0–2.3; p = 0.14 by log-rank). A group of 346 children were vaccinated according to protocol (ATP). Among these children, the hazard ratio was 1.3 (95% CI 0.8–2.1; p = 0.55 by log-rank). When multiple malaria episodes were included in the analyses, the incidence rate ratios were 1.6 (95% CI 1.1–2.3); p = 0.017 for ITT, and 1.4 (95% CI 0.9–2.1); p = 0.16 for ATP. Haemoglobin and parasitaemia in cross-sectional surveys at 3 and 9 mo did not differ by treatment group. Among children vaccinated with FFM ME-TRAP, there was no correlation between immunogenicity and malaria incidence. CONCLUSIONS: No protection was induced against febrile malaria by this vaccine regimen. Future field studies will require vaccinations with stronger immunogenicity in children living in malarious areas. |
format | Text |
id | pubmed-1617125 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-16171252007-04-12 A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya Bejon, Philip Mwacharo, Jedidah Kai, Oscar Mwangi, Tabitha Milligan, Paul Todryk, Stephen Keating, Sheila Lang, Trudie Lowe, Brett Gikonyo, Caroline Molyneux, Catherine Fegan, Greg Gilbert, Sarah C Peshu, Norbert Marsh, Kevin Hill, Adrian V. S PLoS Clin Trials Research Article OBJECTIVE: The objective was to measure the efficacy of the vaccination regimen FFM ME-TRAP in preventing episodes of clinical malaria among children in a malaria endemic area. FFM ME-TRAP is sequential immunisation with two attenuated poxvirus vectors (FP9 and modified vaccinia virus Ankara), which both deliver the pre-erythrocytic malaria antigen construct multiple epitope–thrombospondin-related adhesion protein (ME-TRAP). DESIGN: The trial was randomised and double-blinded. SETTING: The setting was a rural, malaria-endemic area of coastal Kenya. PARTICIPANTS: We vaccinated 405 healthy 1- to 6-year-old children. INTERVENTIONS: Participants were randomised to vaccination with either FFM ME-TRAP or control (rabies vaccine). OUTCOME MEASURES: Following antimalarial drug treatment children were seen weekly and whenever they were unwell during nine months of monitoring. The axillary temperature was measured, and blood films taken when febrile. The primary analysis was time to a parasitaemia of over 2,500 parasites/μl. RESULTS: The regime was moderately immunogenic, but the magnitude of T cell responses was lower than in previous studies. In intention to treat (ITT) analysis, time to first episode was shorter in the FFM ME-TRAP group. The cumulative incidence of febrile malaria was 52/190 (27%) for FFM ME-TRAP and 40/197 (20%) among controls (hazard ratio = 1.52). This was not statistically significant (95% confidence interval [CI] 1.0–2.3; p = 0.14 by log-rank). A group of 346 children were vaccinated according to protocol (ATP). Among these children, the hazard ratio was 1.3 (95% CI 0.8–2.1; p = 0.55 by log-rank). When multiple malaria episodes were included in the analyses, the incidence rate ratios were 1.6 (95% CI 1.1–2.3); p = 0.017 for ITT, and 1.4 (95% CI 0.9–2.1); p = 0.16 for ATP. Haemoglobin and parasitaemia in cross-sectional surveys at 3 and 9 mo did not differ by treatment group. Among children vaccinated with FFM ME-TRAP, there was no correlation between immunogenicity and malaria incidence. CONCLUSIONS: No protection was induced against febrile malaria by this vaccine regimen. Future field studies will require vaccinations with stronger immunogenicity in children living in malarious areas. Public Library of Science 2006-10-20 /pmc/articles/PMC1617125/ /pubmed/17053830 http://dx.doi.org/10.1371/journal.pctr.0010029 Text en © 2006 Bejon et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Bejon, Philip Mwacharo, Jedidah Kai, Oscar Mwangi, Tabitha Milligan, Paul Todryk, Stephen Keating, Sheila Lang, Trudie Lowe, Brett Gikonyo, Caroline Molyneux, Catherine Fegan, Greg Gilbert, Sarah C Peshu, Norbert Marsh, Kevin Hill, Adrian V. S A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya |
title | A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya |
title_full | A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya |
title_fullStr | A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya |
title_full_unstemmed | A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya |
title_short | A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya |
title_sort | phase 2b randomised trial of the candidate malaria vaccines fp9 me-trap and mva me-trap among children in kenya |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1617125/ https://www.ncbi.nlm.nih.gov/pubmed/17053830 http://dx.doi.org/10.1371/journal.pctr.0010029 |
work_keys_str_mv | AT bejonphilip aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT mwacharojedidah aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT kaioscar aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT mwangitabitha aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT milliganpaul aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT todrykstephen aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT keatingsheila aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT langtrudie aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT lowebrett aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT gikonyocaroline aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT molyneuxcatherine aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT fegangreg aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT gilbertsarahc aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT peshunorbert aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT marshkevin aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT hilladrianvs aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT bejonphilip phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT mwacharojedidah phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT kaioscar phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT mwangitabitha phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT milliganpaul phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT todrykstephen phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT keatingsheila phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT langtrudie phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT lowebrett phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT gikonyocaroline phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT molyneuxcatherine phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT fegangreg phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT gilbertsarahc phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT peshunorbert phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT marshkevin phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya AT hilladrianvs phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya |